NCT02052492View on ClinicalTrials.gov

Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Solid Tumors
Interventions
DRUG

EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)

Trial Locations (2)

31096

Rambam MC, Haifa

52621

Sheba Medical Center, Ramat Gan

Sponsors

Lead Sponsor

Efranat Ltd.
All Listed Sponsors
lead

Efranat Ltd.

INDUSTRY